Effect of withdrawal of statin on C-reactive protein

被引:39
作者
Lee, KT
Lai, WT
Chu, CS
Tsai, LY
Yen, HW
Voon, WC
Sheu, SH
机构
[1] Kaohsiung Med Univ Hosp, Dept Internal Med, Cardiol Sect, Kaohsiung 80708, Taiwan
[2] Kaohsiung Med Univ Hosp, Dept Clin Chem, Kaohsiung 80708, Taiwan
关键词
hyperlipidemia; statin; C-reactive protein;
D O I
10.1159/000080486
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: C-reactive protein is considered a risk factor for coronary artery disease. In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein. Abrupt cessation of statin therapy during treatment could increase the incidence of cardiac events in patients with atherosclerotic heart disease. The changes of C-reactive protein after withdrawal of statin therapy are still unknown. Methods: Twenty patients with hyperlipidemia received statin (atorvastatin, 10 mg/day) therapy for 3 months. The levels of lipid profiles and C-reactive protein were assessed before receiving the statin therapy, immediately after 3 months of therapy, and on the 3 consecutive days after withdrawal of statin treatment. Results: After 3 months of statin therapy, the total cholesterol, low-density lipoprotein cholesterol (LDL-chol), and C-reactive protein were significantly reduced (264.94 +/- 16.23 vs. 183.44 +/- 16.34 mg/dl, 183.17 +/- 34.56 vs. 122.00 +/- 17.66 mg/dl, and 2,309.00 +/- 437.85 vs. 1,257.95 +/- 207.99 ng/ml, respectively). The level of C-reactive protein increased on the second day after withdrawal of statin therapy (2,590.14 +/- 1,045.05 vs. 1,257.95 +/- 207.99 ng/ml); however, the total cholesterol and LDL-chol did not increase during the 3-day period after withdrawal of statin therapy. Conclusions: The increase in the level of C-reactive protein after withdrawal of statin therapy may be a contributing factor to the increased incidence of cardiac events in patients who have abruptly stopped statin therapy. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:166 / 170
页数:5
相关论文
共 30 条
[11]  
Heinrich PC, 1998, Z ERNAHRUNGSWISS, V37, P43
[12]  
Kent Steven M, 2003, Am Heart J, V145, pe8, DOI 10.1067/mhj.2003.34
[13]  
Laufs U, 2000, CIRCULATION, V102, P3104
[14]   Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. [J].
Lindahl, B ;
Toss, H ;
Siegbahn, A ;
Venge, P ;
Wallentin, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1139-1147
[15]   THE PROGNOSTIC VALUE OF C-REACTIVE PROTEIN AND SERUM AMYLOID-A PROTEIN IN SEVERE UNSTABLE ANGINA [J].
LIUZZO, G ;
BIASUCCI, LM ;
GALLIMORE, JR ;
GRILLO, RL ;
REBUZZI, AG ;
PEPYS, MB ;
MASERI, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (07) :417-424
[16]   Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway [J].
McCarty, MF .
MEDICAL HYPOTHESES, 2003, 60 (05) :634-639
[17]  
Morrow DA, 2000, CLIN CHEM, V46, P453
[18]   Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients [J].
Mueller, C ;
Buettner, HJ ;
Hodgson, JM ;
Marsch, S ;
Perruchoud, AP ;
Roskamm, H ;
Neumann, FJ .
CIRCULATION, 2002, 105 (12) :1412-1415
[19]  
OLIVER MF, 1994, CARDIOVASC CLIN N AM, V78, P41
[20]   Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. [J].
Packard, CJ ;
O'Reilly, DSJ ;
Caslake, MJ ;
McMahon, AD ;
Ford, I ;
Cooney, J ;
Macphee, CH ;
Suckling, KE ;
Krishna, M ;
Wilkinson, FE ;
Rumley, A ;
Lowe, GDO .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1148-1155